11/7/2011

Disclosure Under Chapter 2 Section 10

ORION CORPORATION STOCK EXCHANGE RELEASE 7 November 2011 at
12:40 EET

Orion Corporation (business code 1999212-6) has received a disclosure under Chapter 2, Section 9 of the Securities Markets Act, according to which the total number of the voting rights of the Orion shares owned by Erkki Etola and a company controlled by him, has in consequence of the share conversion under the Articles of Association of Orion Corporation executed on 7 November 2011 exceeded the one twentieth (1/20) threshold of the total number of Orion Corporation voting rights.

The total holding of  Erkki Etola and the company controlled by him according to the disclosure (percentages rounded):

Share typeNumber of sharesPercent (%) of
total shares
Percent (%)
voting rights
A share2,500,000 1.775.00
ISIN:FI0009014369
    Etola Oy2,300,0001.634.60
    Erkki Etola   200,0000.140.40
B share000
ISIN:FI0009014377
Total2,500,000 1.775.00

Orion Corporation's share capital comprises 141,257,828 shares, of which 45,194,218 are A shares and 96,063,610 are B shares. Each A share entitles its holder to twenty (20) votes and each B share to one (1) vote. Thus, the total number of votes is 999,947,970.                                                                                                                                   

Orion Corporation

Timo Lappalainen                       Olli Huotari
President and CEO                    SVP, Corporate Functions

Contact person:
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.